Replies to post #249704 on Biotech Values

[north40000]

PFE’s salesforce has been marketing/selling AMRN’s orally dosed Vascepa in Canada for U.S. FDA-approved CVD indications in collaboration with HLTRF, AMRN’s partner in the Canadian provinces. Neither PFE nor HLTRF has disclosed info other than increasing Vascepa sales/revenue volume.
I have been prescribed Vascepa to reduce CVD risk since April 2013, and have lost ~ 25-30 lbs while lowering the prescribed dosages of LLY’s Humulin and Humalog to avoid far more hypoglycemic reactions than I had experienced since 1957 when T1-D first ensued. At age 86, I now again weigh ~ 150-155 lbs, my college weight in1955-1959.

[DewDiligence]

Time to update your table vis-à-vis Danuglipron BID. Extended-release (qD) Danuglipron still has a chance to work out, but it has to be considered a high-risk program at this point.